Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer

Background: S-1, a novel oral fluoropyrimidine, is well tolerated in patients with metastatic colorectal cancer (mCRC). The response rate of S-1 for colorectal cancer is high, ranging from 35% to 40%. This study aimed to evaluate the safety and efficacy of S-1 combined with oral leucovorin (LV) to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Koizumi, W., Boku, N., Yamaguchi, K., Miyata, Y., Sawaki, A., Kato, T., Toh, Y., Hyodo, I., Nishina, T., Furuhata, T., Miyashita, K., Okada, Y.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844944/
https://www.ncbi.nlm.nih.gov/pubmed/19828562
http://dx.doi.org/10.1093/annonc/mdp371

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844944/
https://www.ncbi.nlm.nih.gov/pubmed/19828562
http://dx.doi.org/10.1093/annonc/mdp371

Ejemplares similares